Spring is coming, so is Zika. It’s just a matter of time before public outrage will force governments, the US government in the first place, to invest in confronting Zika virus spread.
“Everything we look at with this (Zika) virus seems to be a little scarier than we initially thought,” Dr. Anne Schuchat, CDC principal deputy director, White House briefing, April 11, 2016.
Zika challenge may prove to be on par with AIDS. As the level of alarm over spread of the Zika virus intensifies, governments all over the world, international organizations and pharmaceutical companies race to contain the threat in all its dimensions: vector control, geographical containment, diagnostic test, R&D of vaccines and antivirals, and establishing infrastructures and mechanisms for possible pandemic mitigation.
The global Zika virus preparedness market is expected to reach $4 Billion by 2022 and grow at CAGR 11% in the period 2017-2022.
The new market study explores Zika virus preparedness market segments, products, technologies and services:
- Zika virus preparedness market by geographic regions and major countries;
- Vaccines (including but not limited DNA vaccines, adjuvants);
- Diagnostic tests;
- Vector surveillance and control by surveillance, mechanical, chemical, biological and genetic control methods;
- Clinical trials;
- Medical supplies (including but not limited to therapeutics and blood transfusion management);
- Government, state and local preparedness;
- Risk communications;
- R&D spending and funding.